Exchange: NASDAQ·Updated 09:51 AM EDT
AZN logo

AZNAstraZeneca PLC

$169.78
$0.44
(0.26%)
Today
Reported EarningsApr 29
Mkt Cap$262.62B
Vol67,636.00
News
all
press releases
Why CELC Stock Declined 15% in a Week Despite a Major FDA Win
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Zacks
More News
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $164.52, moving 2.59% from the previous trading session.
Zacks
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Zacks
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, July 16, 2026 AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN PR Newswire NEW YORK, July 16, 2026 NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
Zacks
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
Zacks
AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR cardiomyopathy. If you suffered a loss on your AstraZeneca investment, you are encouraged to submit your...
Business Wire
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.
Zacks
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
Zacks
<
1
2
...
>

Advertisement|Remove ads.